Imatinib mesylate-induced repigmentation of vitiligo lesions in a patient with recurrent gastrointestinal stromal tumors

Journal of the American Academy of Dermatology

Volumn 59, Issue 5 SUPPL., 2008, Pages

  Han, Hui ^a   Yu, Yang yang ^a   Wang, Yu hong ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB;

AGED; ARTICLE; CASE REPORT; CHINESE; DNA SEQUENCE; GASTROINTESTINAL STROMAL TUMOR; HUMAN; HYPERPIGMENTATION; MALE; MISSENSE MUTATION; ONCOGENE C KIT; PRIORITY JOURNAL; VITILIGO;

AGED; GASTROINTESTINAL STROMAL TUMORS; HUMANS; HYPOPIGMENTATION; MALE; MELANINS; NEOPLASM RECURRENCE, LOCAL; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; VITILIGO;

EID: 53349117709     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2008.06.029     Document Type: Article

References (45)

1. Goettsch W.G., Bos S.D., Breekveldt-Postma N., Casparie M., Herings R.M., and Hogendoorn P.C. Incidence of gastrointestinal stromal tumours is underestimated: results of a nation-wide study. Eur J Cancer 41 (2005) 2868-2872
2. Nilsson B., Bumming P., Meis-Kindblom J.M., Oden A., Dortok A., Gustavsson B., et al. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era-a population-based study in western Sweden. Cancer 103 (2005) 821-829
3. Hirota S., Isozaki K., Moriyama Y., Hashimoto K., Nishida T., Ishiguro S., et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279 (1998) 577-580
4. Miettinen M., and Lasota J. KIT (CD117): a review on expression in normal and neoplastic tissues, and mutations and their clinicopathologic correlation. Appl Immunohistochem Mol Morphol 13 (2005) 205-220
5. Corless C.L., Fletcher J.A., and Heinrich M.C. Biology of gastrointestinal stromal tumors. J Clin Oncol 22 (2004) 3813-3825
6. Ishikawa K., Komuro T., Hirota S., and Kitamura Y. Ultrastructural identification of the c-kit-expressing interstitial cells in the rat stomach: a comparison of control and Ws/Ws mutant rats. Cell Tissue Res 289 (1997) 137-143
7. Nocka K., Majumder S., Chabot B., Ray P., Cervone M., Bernstein A., et al. Expression of c-kit gene products in known cellular targets of W mutations in normal and W mutant mice-evidence for an impaired c-kit kinase in mutant mice. Genes Dev 3 (1989) 816-826
8. Turner A.M., Zsebo K.M., Martin F., Jacobsen F.W., Bennett L.G., and Broudy V.C. Nonhematopoietic tumor cell lines express stem cell factor and display c-kit receptors. Blood 80 (1992) 374-381
9. Buchdunger E., Cioffi C.L., Law N., Stover D., Ohno-Jones S., Druker B.J., et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 295 (2000) 139-145
10. Demetri G.D., von Mehren M., Blanke C.D., Van den Abbeele A.D., Eisenberg B., Roberts P.J., et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347 (2002) 472-480
11. Prenen H., Cools J., Mentens N., Folens C., Sciot R., Schoffski P., et al. Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate. Clin Cancer Res 12 (2006) 2622-2627
12. Druker B.J., Sawyers C.L., Kantarjian H., Resta D.J., Reese S.F., Ford J.M., et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 344 (2001) 1038-1042
13. Kantarjian H., Sawyers C., Hochhaus A., Guilhot F., Schiffer C., Gambacorti-Passerini C., et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 346 (2002) 645-652
14. Maeyama H., Hidaka E., Ota H., Minami S., Kajiyama M., Kuraishi A., et al. Familial gastrointestinal stromal tumor with hyperpigmentation: association with a germline mutation of the c-kit gene. Gastroenterology 120 (2001) 210-215
15. Carballo M., Roig I., Aguilar F., Pol M.A., Gamundi M.J., Hernan I., et al. Novel c-KIT germline mutation in a family with gastrointestinal stromal tumors and cutaneous hyperpigmentation. Am J Med Genet A 132 (2005) 361-364
16. Robson M.E., Glogowski E., Sommer G., Antonescu C.R., Nafa K., Maki R.G., et al. Pleomorphic characteristics of a germ-line KIT mutation in a large kindred with gastrointestinal stromal tumors, hyperpigmentation, and dysphagia. Clin Cancer Res 10 (2004) 1250-1254
17. Li F.P., Fletcher J.A., Heinrich M.C., Garber J.E., Sallen S.E., Curiel-Lewandrowski C., et al. Familial gastrointestinal stromal tumor syndrome: phenotypic and molecular features in a kindred. J Clin Oncol 23 (2005) 2735-2743
18. Ronnstrand L. Signal transduction via the stem cell factor receptor/c-Kit. Cell Mol Life Sci 61 (2004) 2535-2548
19. Alexeev V., and Yoon K. Distinctive role of the cKit receptor tyrosine kinase signaling in mammalian melanocytes. J Invest Dermatol 126 (2006) 1102-1110
20. Chabot B., Stephenson D.A., Chapman V.M., Besmer P., and Bernstein A. The proto-oncogene c-kit encoding a transmembrane tyrosine kinase receptor maps to the mouse W locus. Nature 335 (1988) 88-89
21. Spritz R.A. The molecular basis of human piebaldism. Pigment Cell Res 5 (1992) 340-343
22. Fleischman R.A., Saltman D.L., Stastny V., and Zneimer S. Deletion of the c-kit protooncogene in the human developmental defect piebald trait. Proc Natl Acad Sci U S A 88 (1991) 10885-10889
23. Grimes P.E. New insights and new therapies in vitiligo. JAMA 293 (2005) 730-735
24. Kitamura R., Tsukamoto K., Harada K., Shimizu A., Shimada S., Kobayashi T., et al. Mechanisms underlying the dysfunction of melanocytes in vitiligo epidermis: role of SCF/KIT protein interactions and the downstream effector, MITF-M. J Pathol 202 (2004) 463-475
25. Norris A., Todd C., Graham A., Quinn A.G., and Thody A.J. The expression of the c-kit receptor by epidermal melanocytes may be reduced in vitiligo. Br J Dermatol 134 (1996) 299-306
26. Dippel E., Haas N., Grabbe J., Schadendorf D., Hamann K., Czarnetzki D.M., et al. Expression of the c-kit receptor in hypomelanosis: a comparative study between piebaldism, naevus depigmentosus and vitiligo. Br J Dermatol 132 (1995) 182-189
27. Katayama I., Ashida M., Maeda A., Eishi K., Murota H., and Bae S.J. Open trial of topical tacalcitol [1 alpha 24(OH)2D3] and solar irradiation for vitiligo vulgaris: upregulation of c-Kit mRNA by cultured melanocytes. Eur J Dermatol 13 (2003) 372-376
28. Montone K.T., van Belle P., Elenitsas R., and Elder D.E. Proto-oncogene c-kit expression in malignant melanoma: protein loss with tumor progression. Mod Pathol 10 (1997) 939-944
29. Wilson J., Connock M., Song F., Yao G., Fry-Smith A., Rafferty J., et al. Imatinib for the treatment of patients with unresectable and/or metastatic gastrointestinal stromal tumours: systematic review and economic evaluation. Health Technol Assess 9 (2005) 1-142
30. Brouard M., and Saurat J.H. Cutaneous reactions to STI571. N Engl J Med 345 (2001) 618-619
31. Scheinfeld N. Imatinib mesylate and dermatology. Part 2: a review of the cutaneous side effects of imatinib mesylate. J Drugs Dermatol 5 (2006) 228-231
32. Sunita D.K.G., Saluja S., Bhasin S., and Sharma M. Imatinib mesylate-induced generalized hypomentation in patients with chronic myeloid leukemia. Indian J Pharmacol 38 (2006) 66-67
33. Brazzelli V., Roveda E., Prestinari F., Barbagallo T., Bellani E., Trevisan V., et al. Vitiligo-like lesions and diffuse lightening of the skin in a pediatric patient treated with imatinib mesylate: a noninvasive colorimetric assessment. Pediatr Dermatol 23 (2006) 175-178
34. Sharma A., Vora A., and Bhutani M. Generalized hypopigmentation due to imatinib: a fairness boon?. Indian J Dermatol Venereol Leprol 71 (2005) 45-46
35. McPartlin S., and Leach M. Loss of skin pigment caused by imatinib therapy. Br J Haematol 129 (2005) 448
36. Legros L., Cassuto J.P., and Ortonne J.P. Imatinib mesilate (Glivec): a systemic depigmenting agent for extensive vitiligo?. Br J Dermatol 153 (2005) 691-692
37. Leong K.W., Lee T.C., and Goh A.S. Imatinib mesylate causes hypopigmentation in the skin. Cancer 100 (2004) 2486-2487 author reply 2487-8
38. Grossman W.J., and Wilson D.B. Hypopigmentation from imatinib mesylate (Gleevec). J Pediatr Hematol Oncol 26 (2004) 214
39. Tsao A.S., Kantarjian H., Cortes J., O'Brien S., and Talpaz M. Imatinib mesylate causes hypopigmentation in the skin. Cancer 98 (2003) 2483-2487
40. Hasan S., Dinh K., Lombardo F., Dawkins F., and Kark J. Hypopigmentation in an African patient treated with imatinib mesylate: a case report. J Natl Med Assoc 95 (2003) 722-724
41. Brazzelli V., Prestinari F., Barbagallo T., Rona C., Orlandi E., Passamonti F., et al. A long-term time course of colorimetric assessment of the effects of imatinib mesylate on skin pigmentation: a study of five patients. J Eur Acad Dermatol Venereol 21 (2007) 384-387
42. Raanani P., Goldman J.M., and Ben-Bassat I. Challenges in oncology. Case 3. Depigmentation in a chronic myeloid leukemia patient treated with STI-571. J Clin Oncol 20 (2002) 869-870
43. Grichnik J.M., Burch J.A., Burchette J., and Shea C.R. The SCF/KIT pathway plays a critical role in the control of normal human melanocyte homeostasis. J Invest Dermatol 111 (1998) 233-238
44. Singh N., and Bakhshi S. Imatinib-induced dental hyperpigmentation in childhood chronic myeloid leukemia. J Pediatr Hematol Oncol 29 (2007) 208-209
45. Prabhash K., Biswas G., Prasad N., Karant N., Sastry P.S., and Parikh P.M. Imatinib-induced nail hyperpigmentation in chronic myeloid leukemia. Indian J Dermatol Venereol Leprol 72 (2006) 63-64